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Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and
is associated with a number of potential outcomes, including impaired diastolic function,
heart failure, and sudden cardiac death. Various etiologies have been described for
HCM, including pressure overload and mutations in sarcomeric and non-sarcomeric
genes. However, the molecular pathogenesis of HCM remains incompletely understood.
In this study, we performed comparative transcriptome analysis to identify dysregulated
genes common to five mouse HCM models of differing etiology: (i) mutation of myosin
heavy chain 6, (ii) mutation of tropomyosin 1, (iii) expressing human phospholamban
on a null background, (iv) knockout of frataxin, and (v) transverse aortic constriction.
Gene-by-gene comparison identified five genes dysregulated in all five HCM models.
Glutathione S-transferase kappa 1 (Gstk1) was significantly downregulated in the
five models, whereas myosin heavy chain 7 (Myh7), connective tissue growth factor
(Ctgf ), periostin (Postn), and reticulon 4 (Rtn4) were significantly upregulated. Gene
ontology comparison revealed that 51 cellular processes were significantly enriched
in genes dysregulated in each transcriptome dataset. Among them, six processes
(oxidative stress, aging, contraction, developmental process, cell differentiation, and cell
proliferation) were related to four of the five genes dysregulated in all HCM models.
GSTK1 was related to oxidative stress only, whereas the other four genes were related to
all six cell processes except MYH7 for oxidative stress. Gene–gene functional interaction
network analysis suggested correlative expression of GSTK1, MYH7, and actin alpha 2
(ACTA2). To investigate the implications of Gstk1 downregulation for cardiac function,
we knocked out gstk1 in zebrafish using the clustered regularly interspaced short
palindromic repeats/Cas9 system. We found that expression of the zebrafish homologs
of MYH7, ACTA2, and actin alpha 1 were increased in the gstk1-knockout zebrafish.
In vivo imaging of zebrafish expressing a fluorescent protein in cardiomyocytes showed
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that gstk1 deletion significantly decreased the end diastolic volume and, to a lesser
extent, end systolic volume. These results suggest that downregulation of GSTK1
may be a common mechanism underlying HCM of various etiologies, possibly through
increasing oxidative stress and the expression of sarcomere genes.
Keywords: hypertrophic cardiomyopathy, comparative transcriptomics, GSTK1, mitochondria, oxidative stress,
zebrafish, CRISPR/Cas9, systems pharmacology
INTRODUCTION
Hypertrophic cardiomyopathy is characterized by thickening of
the left ventricle and is associated with a range of potential
outcomes, such as impaired diastolic function, heart failure, and
sudden cardiac death (Semsarian et al., 2015). The prevalence
of HCM is estimated to be ∼1 in 500 people (Semsarian et al.,
2015). HCM has multiple etiologies, including mutation in
sarcomeric genes such as myosin heavy chain 7 (MYH7) and
tropomyosin 1 (TPM1) and in non-sarcomeric genes such as
PLN and FXN (Ho et al., 2015). HCM is also caused by pressure
overload (Lai et al., 2014; Aubert et al., 2016). However, the
molecular mechanisms underlying HCM remain incompletely
understood (Force et al., 2010). In general, mutations in MYH7
and other myosin genes associated with HCM increase the
force-generating capacity of the sarcomere rather than diminish
its function (Poggesi and Ho, 2014). In addition, most HCM-
associated mutations in thin filament regulatory proteins such
as TPM1 increase the Ca2++ sensitivity of force production
(Ashrafian et al., 2011). These findings suggest that compensatory
hypertrophy is unlikely to be the cause of HCM induced
by mutation of sarcomeric genes (Ashrafian et al., 2011).
PLN regulates sarcoplasmic reticulum Ca2+ cycling in the
heart through inhibition of ATPase sarcoplasmic/endoplasmic
reticulum Ca2+ transporting 2 (ATP2A2) (Wang et al., 2011).
Mutation of PLN causing superinhibition of ATP2A2 can cause
HCM (Wang et al., 2011). Haploinsufficiency of ATP2A2 can
also cause HCM, possibly through mitochondrial dysfunction
(Prasad et al., 2015), suggesting that mutation of PLN causing
HCM may impair mitochondrial function. Haploinsufficiency of
FXN is a major cause of FA (Payne and Wagner, 2012). FA is
associated with progressive HCM, and this is a common cause
of death in FA patients (Payne and Wagner, 2012). FXN is
an iron-binding protein targeted to the mitochondrial matrix,
and consistent with this, mitochondrial function is impaired in
FA (Payne and Wagner, 2012). Mitochondrial dysfunction has
also been detected in HCM caused by mutation in sarcomeric
genes (Lucas et al., 2003) and pressure overload (Doenst
et al., 2013). These findings suggest the existence of convergent
Abbreviations: ACTA1, actin alpha 1; ACTA2, actin alpha 2; CRISPR, clustered
regularly interspaced short palindromic repeats; crRNA, CRISPR RNA; CTGF,
connective tissue growth factor; dpf, days-post-fertilization; EDV, end diastolic
volume; ESV, end systolic volume; EF, ejection fraction; DEG, differentially
expressed gene; FA, Friedreich’s ataxia; FXN, frataxin; GEO, Gene Expression
Omnibus; GSTK1, glutathione S-transferase kappa 1; HCM, hypertrophic
cardiomyopathy; KO, knockout; mRFP, monomeric red fluorescent protein;
MYH6, myosin heavy chain 6; MYH7, myosin heavy chain 7; MYL7, myosin light
chain 7; PLN, phospholamban; POSTN, periostin; qPCR, quantitative polymerase
chain reaction; RTN4, reticulon 4; SRF, serum response factor; TAC, transverse
aortic constriction; TF, transcription factor; TPM1, tropomyosin 1.
pathways that cause HCM by impairment of mitochondrial
function.
Comparative transcriptomics could represent a new frontier
in the search for novel biomarkers and/or therapeutic targets
in diseases with multiple etiologies because it facilitates the
identification of dysregulated genes common to all disease
etiologies (Sasagawa et al., 2016b). In this study, we sought to
identify DEGs common to five different mouse models of HCM.
The transcriptome datasets were downloaded from a public
database (Barrett et al., 2009) and were derived from mouse
models of HCM caused by: (i) mutation of myosin heavy chain 6
(Myh6) (Luczak et al., 2011), (ii) mutation of Tpm1 (Rajan et al.,
2013), (iii) expressing human PLN on a null background (Wang
et al., 2011), (iv) KO of Fxn (Huang et al., 2013), and (v) TAC, a
model of pressure overload-induced HCM (Lai et al., 2014). We
identified five genes dysregulated in all five HCM transcriptome
datasets, among which glutathione S-transferase kappa 1 (Gstk1)
was the only gene downregulated. We were particularly interested
in this gene because Gstk1 is localized in mitochondria and
peroxisomes (Petit et al., 2009). We examined the function of
gstk1 in zebrafish, which has emerged as a useful in vivo model
to study human genetic disorders including HCM (Becker et al.,
2012). We demonstrate here that knockout of gstk1 in zebrafish
increased the expression of HCM marker genes and decreased
the cardiac EDV and, to a lesser extent, the ESV, suggesting
that downregulation of GSTK1 may be a common mechanism
underlying HCM of various etiologies.
MATERIALS AND METHODS
Ethics Statement
This study was carried out in strict accordance with Japanese
law [The Humane Treatment and Management of Animals
(2014), Standards Relating to the Care and Management of
Laboratory Animals and Relief of Pain (2013), and the Guidelines
for Proper Conduct of Animal Experiments (Science Council
of Japan, 2006)] (Science Council of Japan, 2006; Ministry of
the Environment Japan, 2013, 2014). All efforts were made to
minimize animal suffering. Mie University Institutional Animal
Care and Use Committee guidelines state that no approval is
required for experiments using zebrafish.
Comparative Transcriptome Analysis
Among the transcriptome datasets analyzing HCM caused by
mutation or KO of 23 genes listed in Table 1 of Ho et al.
(2015), including cardiac troponin T (TNNT2), cardiac troponin
I (TNNI3), and cardiac myosin-binding protein C (MYBPC3),
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in the GEO (Barrett et al., 2009), we selected datasets satisfying
all of the following criteria: (i) using mice 2–4 months old
when RNA was extracted, (ii) using mice fed with a standard
diet without any supplementation, (iii) analyzing the expression
profile of mRNAs but not microRNAs or non-coding RNAs,
(iv) with downloadable raw data or normalized data, with the
quality of each probe signal available, and (v) having control
and HCM groups with at least two samples in each group. Four
transcriptome datasets passed these criteria. In the Myh6 model
(GSE25700) (Luczak et al., 2011), C57BL/6 mice overexpressed
a rat Myh6 transgene containing a point mutation (R403Q) and
a deletion of amino acids 468–527 was replaced with nine non-
myosin amino acids (Myh6-R403Q-d50) (Vikstrom et al., 1996).
Hearts from wild-type or HCM C57BL/6 mice were excised at
2 months of age and subjected to transcriptome analysis. In the
Tpm1 mutation model (GSE42892; Rajan et al., 2013), FVB/N
mice overexpressed mouse Tpm1 containing a point mutation
resulting in E180G (Tpm1-E180G). Hearts from wild-type or
HCM FVB/N mice were excised at 4 months of age and subjected
to transcriptome analysis. In the human PLN model (GSE20172)
(Wang et al., 2011), hearts from wild-type or transgenic mice
expressing human PLN on a null background were excised at
11 weeks of age and used for transcriptome analysis. In the
Fxn-KO model (GSE31208; Huang et al., 2013), hearts from
wild-type or muscle creatine kinase conditional Fxn-KO mice
were excised at 10 weeks of age and subjected to transcriptome
analysis. We also included a transcriptome dataset analyzing
HCM caused by TAC, because it is a representative murine
model of cardiac hypertrophy (Rockman et al., 1991). In the TAC
model (GSE56348; Lai et al., 2014), hearts were excised from
C57BL/6J mice 1 month after TAC or sham surgery performed at
8-week-old and subjected to transcriptome analysis. The raw data
were normalized using “affy” (Gautier et al., 2004) for GSE25700
and GSE31208, “oligo” (Carvalho et al., 2007) for GSE42892
and GSE56348, and “limma” (Ritchie et al., 2015) for GSE20172
in Bioconductor (Gentleman et al., 2004). Probes with reliable
signals were selected and subjected to “RankProd” (Hong et al.,
2006) to identify DEGs in the HCM mice compared with the
relevant control mice using a false discovery rate (FDR) of 20% as
the threshold. The gene symbols of the DEGs in each model were
converted to those of the human orthologous genes using Life
Science Knowledge Bank (World Fusion, Tokyo, Japan). The list
of DEGs in each HCM model is shown in Supplementary Tables
S1-1–S1-5.
Bioinformatic Analysis of the DEGs in the
Five HCM Models
To identify cellular processes significantly enriched for each DEG
identified in each HCM model, we used Pathway Studio (Nikitin
et al., 2003) that uses gene sets derived from natural language
processing-based text mining of published literature in relation to
biological functions such as cellular processes, expression targets,
and binding partners. The lists of DEGs shown in Supplementary
Tables S1-1–S1-5 were subjected to Pathway Studio and used
to predict the cellular processes significantly enriched, using
subnetwork enrichment analysis. The predicted cellular processes
with p < 1.0 × 10−5 are shown in Supplementary Tables S2-1–
S2-5. Common cellular processes among Supplementary Tables
S2-1–S2-5 are shown in Supplementary Table S2-6.
To identify networks related to the five genes dysregulated in
all five mouse HCM models, we used GeneMANIA in Cytoscape
(Shannon et al., 2003) with the default settings. GeneMANIA uses
a database of organism-specific weighted networks to construct
a weighted composite functional interaction network between
a pair of genes, including physical interaction, co-expression,
pathway, co-localization, and shared protein domains, from a list
of genes (Montojo et al., 2014). The networks related to the five
common DEGs are shown in Supplementary Tables S3-1–S3-6.
The gene score calculated based on these functional interactions
is shown in Supplementary Table S3-7.
We used iRegulon to identify TFs potentially regulating the
five DEGs common to the HCM models (Janky et al., 2014).
iRegulon exploits the fact that genes co-regulated by the same
TF often contain common TF-binding sites. iRegulon has been
successfully used to identify TFs in gene lists (Sasagawa et al.,
2016a) using ENCODE ChIP-seq data as a reference database
(Gerstein et al., 2012). The five common DEGs were subjected
to iRegulon using a normalized enrichment score of 5 as
the threshold. The predicted TFs are listed in Supplementary
Table S4.
Zebrafish Strains
We obtained Tg (myl7:mRFP) zebrafish, which express mRFP
under the control of the myosin light chain 7 (myl7) promoter,
a gene selectively expressed in cardiomyocytes (Kawahara et al.,
2009), from the National BioResource Project Zebrafish (Saitama,
Japan). Zebrafish were bred and maintained according to
previously described methods (Westerfield, 2007; Nishimura
et al., 2016). Briefly, zebrafish were raised at 28.5◦C ± 0.5◦C
with a 14-h/10-h light/dark cycle. Embryos were obtained by
natural mating and cultured in 0.3×Danieau’s solution (19.3 mM
NaCl, 0.23 mM KCl, 0.13 mM MgSO4, 0.2 mM Ca(NO3)2,
1.7 mM HEPES, pH 7.2) until 5 dpf, at which time they were
used for the in vivo imaging analyses or were processed for
qPCR.
Knockout of gstk1 in Zebrafish
KO of gstk1 in zebrafish was performed by the ready-
to-use CRISPR/Cas9 method (Aida et al., 2015). CRISPR
RNA (crRNA) targeting a 5′-ATTGTCTCAAAAACGTTGGA-3′
sequence in the gstk1 genome and trans-activating crRNA
(tracrRNA) were obtained from FASMAC (Kanagawa, Japan).
Recombinant Cas9 protein was obtained from Toolgen (Seoul,
South Korea). In brief, crRNA, tracrRNA, and Cas9 protein were
dissolved in sterilized water at concentrations of 250, 1000, and
1000 ng/µL, respectively, and stored at −80◦C until required.
For microinjection, the crRNA, tracrRNA, Cas9 protein, and a
lissamine-labeled control morpholino with no known target gene
(Gene Tools, Philomath, OR, USA) were mixed in Yamamoto’s
Ringer’s solution (0.75% NaCl, 0.02% KCl, 0.02% CaCl2, 0.002%
NaHCO3) to final concentrations of 100, 100, 400 ng/µL, and
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50 nM, respectively. The solution was injected into one- to four-
cell-stage zebrafish embryos derived from the Tg (myl7:mRFP)
line.
At 1 dpf, the embryos exhibiting bright lissamine fluorescence
were selected and maintained until 5 dpf. At 5 dpf, the selected
zebrafish were used for in vivo imaging of the cardiac ventricles or
were processed for qPCR. After completion of the in vivo imaging
experiments, genomic DNA was extracted from the zebrafish by
incubation in 50 µL of lysis buffer (10 mM Tris–HCl, pH 8.0,
0.1 mM EDTA, 0.2% Triton X-100, 200 µg/mL proteinase K)
at 55◦C overnight, followed by incubation at 99◦C for 10 min.
The solution was then placed at 4◦C and used as the template
for PCR. To detect the crRNA-induced mutations, we performed
a heteroduplex mobility assay (Kotani et al., 2015). Briefly, a
short fragment of the gstk1 gene encompassing the crRNA target
sites was amplified from the genomic DNA using gstk1_gF1
and gstk1_gR1 primers and QuickTaq (Toyobo, Osaka, Japan).
PCR cycling conditions were: 94◦C for 2 min followed by 40
cycles of 94◦C for 30 s, 60◦C for 30 s, and 68◦C for 30 s.
The PCR products were electrophoresed on 10% polyacrylamide
gels (Wako Chemicals) and visualized by ethidium bromide
staining. The result is shown in Supplementary Figure S2. The
crRNA, tracrRNA, and PCR primer sequences are shown in
Supplementary Table S5.
In Vivo Imaging of the Zebrafish Heart
Tg (myl7:mRFP) zebrafish at 5 dpf were transferred onto glass
slides. A few drops of 3% low-melting point agarose were laid
over the living larvae, which were immediately placed on their
backs. The ventricles of the embedded larvae were observed using
an epifluorescence microscope (SMZ25; Nikon, Tokyo, Japan)
with RFP filters, and images were recorded at 100 frames/s for
10 s. Quantitative assessment of cardiac function was performed
using ImageJ (Schneider et al., 2012) and Volocity software
(Perkin Elmer, Cambridge, MA, USA). Briefly, the time-lapse
images were processed using the Fast Fourier Transform package
in ImageJ to reduce the background noise, and the long and short
diastolic and systolic diameters of the ventricle were measured
using Volocity. The EDV and ESV were calculated using the
diameters. The EF was calculated from the EDV and ESV.
Quantitative PCR Analysis
Total RNA was extracted from control or gstk1-KO zebrafish at
5 dpf using an RNAqueous Micro Kit (Takara, Kyoto, Japan)
according to the manufacturer’s protocol. RNA concentrations
were determined using a NanoDrop spectrophotometer (Thermo
Scientific, Waltham, MA, USA), and cDNAs were generated
using a ReverTra Ace qPCR RT Kit (Toyobo). Quantitative
PCR (qPCR) was performed using an ABI Prism 7300 (Life
Technologies Carlsbad, CA, USA) with THUNDERBIRD SYBR
qPCR Mix (Toyobo). The thermal cycling conditions were: 95◦C
for 1 min followed by 40 cycles of 95◦C for 15 s, 60◦C for 15 s,
and 72◦C for 45 s. We measured the expression of actin alpha 1a
(acta1a), actin alpha 1b (acta1b), ventricular myosin heavy chain
(vmhc), actin-related protein 1 (arp1), connective tissue growth
factor a (ctgfa), periostin, osteoblast specific factor b (postnb) and
glyceraldehyde-3-phosphate dehydrogenase (gapdh) mRNA. The
acta1a, acta1b, vmhc, arp1, ctgfa, and postnb mRNA levels were
normalized to gapdh mRNA levels to correct for variability in the
initial template concentration and the conversion efficiency of the
reverse transcription reaction. The primer sequences are shown
in Supplementary Table S5.
Statistical Analysis
Statistical analysis was performed using Prism 6 (GraphPad, La
Jolla, CA, USA). Group means were compared by the Mann–
Whitney U test with alpha set at 0.05. Data are shown as the
mean± standard error (SEM).
RESULTS
Identification of Dysregulated Genes
Common to the Five Mouse HCM Models
To identify genes dysregulated in HCM of differing etiologies, we
downloaded transcriptome datasets from studies of five mouse
models of HCM (Luczak et al., 2011; Wang et al., 2011; Huang
et al., 2013; Rajan et al., 2013; Lai et al., 2014) from GEO (Barrett
et al., 2009). We identified 966, 118, 866, 247, and 1349 DEGs in
HCM caused by mutation of Myh6, mutation of Tpm1, a human
PLN transgene, KO of Fxn1, and TAC, respectively, compared
with the relevant controls (Supplementary Tables S1-1–S1-5).
A Venn diagram showing unique and shared DEGs is shown in
Figure 1. Five DEGs were either upregulated or downregulated in
all five datasets (Table 1). Expression of glutathione S-transferase
kappa 1 (Gstk1) was significantly decreased in the five HCM
transcriptome datasets, whereas connective tissue growth factor
(Ctgf ), myosin heavy chain 7 (Myh7), periostin (Postn), and
reticulon 4 (Rtn4) were significantly increased in all datasets.
These results suggest that these five DEGs may be robust
biomarkers of HCM caused by multiple mechanisms.
Identification of Functional Interaction
Networks Related to the Common DEGs
We then analyzed the cellular processes significantly enriched
for the DEGs identified in each HCM transcriptome dataset.
The identified processes are shown in Supplementary Tables
S2-1–S2-5. Fifty-one cellular processes were common to the
five transcriptome datasets (Figure 2A; Supplementary Table
S2-6). Among these, six (oxidative stress, aging, contraction,
developmental process, cell differentiation, and cell proliferation)
were related to four of the five genes dysregulated in all HCM
models (Figure 2B). GSTK1 was related to oxidative stress only,
whereas the other four genes were related to all six cell processes,
except MYH7 for oxidative stress. These results suggest that
increased oxidative stress may be a common pathophysiological
mechanism in HCM.
We next analyzed the functional interaction networks related
to the five common DEGs using GeneMANIA (Montojo et al.,
2014). The networks identified by GeneMANIA are shown
in Figure 3 and Supplementary Tables S3-1–S3-7. GSTK1 is
connected to MYH7 and RTN4 through actin-related protein 1
homolog B (ACTR1B) and to CTGF and POSTN through actin
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00 α2 (ACTA2) as co-expressed genes (Supplementary Table S3-1).
GSTK1 is also connected to adiponectin (ADIPOQ) by sharing
a physical interaction (Supplementary Table S3-2). These results
suggest that down-regulation of GSTK1 may affect the expression
of co-expressed genes in the network and impair pathways related
to ADIPOQ.
We also analyzed the TFs potentially regulating the common
DEGs using iRegulon (Janky et al., 2014). The identified TFs are
shown in Supplementary Figure S1 and Table S4. Eight TFs were
identified, including TATA-binding protein (TBP), SRF, TEA
domain family member 1 (TEAD1), and nuclear transcription
factor Y beta (NFYB) as TFs possibly regulating the transcription
of MYH7, CTGF, RTN4, and/or POSTN. SRF is known to be
activated in HCM (Chai and Tarnawski, 2002). These results
suggest that SRF may be activated in the five HCM models.
However, no TFs were identified in this analysis as regulating
GSTK1 (Supplementary Table S4).
gstk1 Knockout Increases Expression of
the Zebrafish Homologs of ACTA2
To determine whether reduction of GSTK1 affects expression
of genes co-expressed in the functional interaction networks
identified by GeneMANIA, we knocked out gstk1 in zebrafish
using the CRISPR/Cas9 system (Aida et al., 2015). Recent
technological advances in genome editing have enabled us to
make KO zebrafish for any gene of interest and validated the
characterization of KO zebrafish at F0 (Kotani et al., 2015;
Sasagawa et al., 2016b). As shown in Supplementary Figure
S2, multiple heteroduplexes (red line) above the homoduplex
(black arrowhead) were observed when PCR was performed
using genomic DNA from zebrafish injected with crRNA for
gstk1. These results suggest that the gstk1 crRNA efficiently
edited the gstk1 gene, resulting in gstk1-KO. We then performed
qPCR to examine the effect of gstk1-KO on the expression
of acta1a, acta1b, vmhc, actr1, ctgfa, and postnb, the zebrafish
homologs of ACTA2, ACTA1, MYH7, ACTR1B, CTGF, and
POSTN, respectively. As shown in Figure 4, acta1a expression
was significantly increased in gstk1-KO zebrafish compared with
the control zebrafish line. The expression of acta1b and vmhc
was slightly increased in the gstk1-KO zebrafish (p = 0.05
and 0.06, respectively). By contrast, there were no significant
differences in actr1, ctgfa, and postnb expression between the
gstk1-KO and control zebrafish. These results suggest that GSTK1
downregulation may increase the expression of sarcomeric genes,
including ACTA2, ACTA1, and MYH7.
gstk1 Knockout Decreases the Cardiac
End Diastolic and Systolic Volume in
Zebrafish
We next investigated the cardiac function of gstk1-KO zebrafish
expressing mRFP in cardiomyocytes. The animals were examined
by fluorescence microscopy and images were captured for
measurement of diastolic and systolic diameters and calculation
of EDV, ESV, and EF. We observed that the EDV in gstk1-
KO zebrafish was significantly smaller than that of control
zebrafish (Figure 5). The ESV was also significantly reduced
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FIGURE 1 | Venn diagram of differentially expressed genes in the five hypertrophic cardiomyopathy (HCM) transcriptome datasets. Transcriptome data
from the mouse HCM models caused by (i) mutation of Myh6 (GSE25700), (ii) mutation of Tpm1 (GSE42892), (iii) human PLN transgene (GSE20172), (iv) KO of Fxn
(GSE31208), and (v) TAC (GSE56348) were downloaded from GEO. Genes that were differentially expressed in the HCM and control groups of each dataset were
identified using a FDR of 20% as the threshold. The numbers of differentially expressed genes unique to each transcriptome dataset and shared between datasets
are shown.
in gstk1-KO zebrafish compared with that in control zebrafish,
albeit to a lesser extent than the EDV. These results suggest
that downregulation of GSTK1 and subsequent upregulation
of sarcomeric genes may be a common pathophysiological
mechanism in HCM.
DISCUSSION
MYH7, CTGF, POSTN, RTN4, and GSTK1
are Dysregulated in HCM
We demonstrated that expression of Myh7, Ctgf, Postn,
and Rtn4 is significantly increased and expression of Gstk1
is significantly decreased in five mouse HCM models.
These results suggest that the five genes may be robust
biomarkers of disease and/or involved in the pathogenesis
of HCM.
MYH7, which encodes cardiac muscle β myosin heavy
chain, is the major sarcomeric protein. Expression of MYH7
is increased in the hearts of HCM patients compared with
healthy subjects (Kontaraki et al., 2007). Our bioinformatic
analysis revealed that SRF may increase the expression of MYH7,
consistent with previous reports (Nelson et al., 2005). These
findings suggest that MYH7 upregulation, possibly through
SRF activation, may be a common pathophysiological pathway
in HCM.
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FIGURE 2 | Cell processes related to the five genes dysregulated in all five HCM transcriptome datasets. (A) Venn diagram of cellular processes
significantly enriched for differentially expressed genes identified in each HCM transcriptome dataset. The numbers of cellular processes unique to each
transcriptome dataset and shared between datasets are shown. (B) Network among the five genes dysregulated in all five HCM transcriptome datasets, and cellular
processes that connect four of the five dysregulated genes.
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FIGURE 3 | Functional interaction networks related to the five genes dysregulated in all five HCM transcriptome datasets. The five genes (shown in
black circles) were subjected to GeneMANIA searches. The functional interaction networks identified by GeneMANIA are shown. Co-expression (Supplementary
Table S3-1), physical interaction (Supplementary Table S3-2), predicted (Supplementary Table S3-3), pathway (Supplementary Table S3-4), co-localization
(Supplementary Table S3-5), and shared protein domain (Supplementary Table S3-6) interactions are shown in purple, russet, orange, sky, aqua, and green lines,
respectively. The size of the gray circles denotes the score in the functional network (Supplementary Table S3-7).
CTGF and POSTN are extracellular matrix proteins regulated
by TGFβ signaling (Grotendorst, 1997; Horiuchi et al., 1999).
Previous work has shown that Ctgf and Postn expression is
increased in mouse models of HCM caused by Myh6-R403Q
(Teekakirikul et al., 2010; Tsoutsman et al., 2013) and by KO of
Mybpc3 (Judge et al., 2015). It was suggested that the source of
Ctgf and Postn may be cardiac fibroblasts (Teekakirikul et al.,
2010; Seidman and Seidman, 2011). TGFβ signaling is activated
in various HCM models, and inhibition of TGFβ reduces fibrosis
and limits hypertrophy remodeling (Teekakirikul et al., 2010;
Seidman and Seidman, 2011). Thus, increased expression of
CTGF and POSTN, potentially via TGFβ signaling, may underlie
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FIGURE 4 | gstk1 knockout in zebrafish increases the expression of acta1a qPCR analysis of acta1a, acta1b, vmhc, actr1, ctgfa, and postnb mRNA
levels in control and gstk1-knockout (KO) zebrafish at 5 dpf. Expression was normalized to gapdh mRNA levels. N = 8 per group. ∗p < 0.05 vs. control group.
the fibrosis and collagen deposition associated with HCM of
various etiologies.
RTN4, also called Nogo-A, is enriched in endoplasmic
reticulum and known to be increased in genetic models
of dilated cardiomyopathy and in end-stage heart
failure in humans (Bullard et al., 2008). Knockdown
of Nogo-A inhibited hypoxia/reoxygenation-induced
activation of mitochondrial-dependent apoptosis in
cardiomyocytes (Sarkey et al., 2011). These findings
suggest that increased expression of RTN4 may also
be associated with HCM through impairment of
mitochondria.
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FIGURE 5 | gstk1 knockout decreases the cardiac end diastolic and systolic volumes in zebrafish. (A) In vivo imaging of the hearts of control and
gstk1-knockout (KO) Tg (myl7:mRFP) zebrafish at 5 dpf. Zebrafish were placed on slides on their backs, and the heart was imaged under a fluorescence microscope
at 100 frames/s for 10 s. Image stack projections and the M-mode imaging of ventricles are shown. Bar, 100 µm. (B) Quantitative analysis of the in vivo imaging of
zebrafish heart. The end diastolic volume (EDV) of gstk1-KO zebrafish was significantly smaller than that of control zebrafish, whereas the end systolic volume (ESV)
and ejection fraction (EF) were not significantly different. N = 13 and 7 for the control and gstk1-KO groups, respectively. ∗p < 0.05, ∗∗∗p < 0.001 vs. control group.
GSTK1 is a member of the κ class of glutathione S-transferases
and is localized in mitochondria and peroxisomes (Morel
et al., 2004; Raza, 2011). Proteomic analysis revealed that
Gstk1 expression is decreased in HCM caused by pressure
overload (Aubert et al., 2016) and diabetic cardiomyopathy
(Das et al., 2015). Gstk1 expression is increased by peroxisome
proliferator-activated receptor α (PPARα) agonists (Knight
et al., 2008). Given that PPARα signaling is impaired
in HCM (Taegtmeyer et al., 2004), these observations
suggest that GSTK1 expression may be reduced, possibly
via inhibition of PPARα, in HCM caused by various
mechanisms.
Reduction of GSTK1 Expression is
Associated with HCM
In this study, we demonstrated that KO of gstk1 in zebrafish
increased the expression of ACTA2, ACTA1, and MYH7
homologs and decreased the EDV and, to a lesser extent,
the ESV, consistent with a possible causative role for GSTK1
downregulation in HCM.
GSTK1 is localized in mitochondria and peroxisomes
(Raza, 2011), which are the important sites for lipid
metabolism and oxygen consumption in cardiomyocytes
(Colasante et al., 2015). Knockdown of gstk1 and gstk2 in
Caenorhabditis elegans impairs oxygen consumption and lipid
metabolism (Petit et al., 2009). In contrast, overexpression
of GSTK1 reduces lipid peroxidation in peroxisomes (Wang
et al., 2013). Peroxisome-derived oxidative stress can cause
mitochondrial damage (Wang et al., 2013). Oxidative stress,
lipid peroxidation, and mitochondrial dysfunction have
been associated with HCM (Vakrou and Abraham, 2014);
the suppression of each function mitigated HCM (Liu
et al., 2012). These findings suggest that down-regulation
of GSTK1 may cause HCM through increased oxidative
stress, lipid peroxidation, and mitochondrial dysfunction.
Increased oxidative stress activates SRF (Jin et al., 2011),
suggesting that down-regulation of GSTK1 may activate SRF
through increasing oxidative stress, resulting in increased
SRF-target genes such as ACTA2, ACTA1, and MYH7 (Miano
et al., 2007). However, the magnitude of the increase in the
homologs of ACTA1 and MYH7 in gstk1-KO zebrafish was
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not strong. Moreover, the expression of the homologs of CTGF
and POSTN was significantly increased in the five mouse HCM
models but not in gstk1-KO zebrafish. These results suggest that
down-regulation of GSTK1 and other signaling pathways may
synergistically cause HCM in mammals. Further studies using
various models such as Gstk1-KO mice and induced pluripotent
stem cells derived from HCM patients will be necessary to
elucidate the detailed mechanisms by which downregulation of
GSTK1 may cause HCM.
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